CN106620897B - 一种抗再狭窄的管腔内支架材料 - Google Patents
一种抗再狭窄的管腔内支架材料 Download PDFInfo
- Publication number
- CN106620897B CN106620897B CN201611201213.6A CN201611201213A CN106620897B CN 106620897 B CN106620897 B CN 106620897B CN 201611201213 A CN201611201213 A CN 201611201213A CN 106620897 B CN106620897 B CN 106620897B
- Authority
- CN
- China
- Prior art keywords
- matrix
- small peptide
- microflute
- coating
- restenosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000463 material Substances 0.000 title claims abstract description 50
- 208000037803 restenosis Diseases 0.000 title claims abstract description 32
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 70
- 239000011159 matrix material Substances 0.000 claims abstract description 66
- 239000011248 coating agent Substances 0.000 claims abstract description 64
- 238000000576 coating method Methods 0.000 claims abstract description 64
- 239000000203 mixture Substances 0.000 claims abstract description 37
- 230000015556 catabolic process Effects 0.000 claims abstract description 34
- 238000006731 degradation reaction Methods 0.000 claims abstract description 34
- 210000002889 endothelial cell Anatomy 0.000 claims abstract description 30
- 229920006237 degradable polymer Polymers 0.000 claims abstract description 26
- 239000000017 hydrogel Substances 0.000 claims abstract description 14
- 238000001338 self-assembly Methods 0.000 claims abstract description 9
- 210000004369 blood Anatomy 0.000 claims abstract description 8
- 239000008280 blood Substances 0.000 claims abstract description 8
- 238000001727 in vivo Methods 0.000 claims abstract description 7
- 239000012530 fluid Substances 0.000 claims abstract description 6
- 230000008520 organization Effects 0.000 claims abstract description 4
- 230000008929 regeneration Effects 0.000 claims abstract description 4
- 238000011069 regeneration method Methods 0.000 claims abstract description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 44
- 150000001875 compounds Chemical class 0.000 claims description 32
- 238000002360 preparation method Methods 0.000 claims description 26
- 229910052742 iron Inorganic materials 0.000 claims description 20
- 239000013522 chelant Substances 0.000 claims description 16
- 229920000642 polymer Polymers 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000000835 fiber Substances 0.000 claims description 14
- 229920002101 Chitin Polymers 0.000 claims description 11
- 229920001610 polycaprolactone Polymers 0.000 claims description 10
- 239000004632 polycaprolactone Substances 0.000 claims description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- 229920001503 Glucan Polymers 0.000 claims description 9
- 229920000954 Polyglycolide Polymers 0.000 claims description 9
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 9
- 229910052751 metal Inorganic materials 0.000 claims description 9
- 239000002184 metal Substances 0.000 claims description 9
- 229920001308 poly(aminoacid) Polymers 0.000 claims description 9
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 9
- 239000004633 polyglycolic acid Substances 0.000 claims description 9
- 239000004626 polylactic acid Substances 0.000 claims description 9
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 9
- 229920001661 Chitosan Polymers 0.000 claims description 8
- 108010010803 Gelatin Proteins 0.000 claims description 7
- JCEGKJFZOJBPOL-UHFFFAOYSA-N ethanol;2-hydroxypropanoic acid Chemical compound CCO.CC(O)C(O)=O JCEGKJFZOJBPOL-UHFFFAOYSA-N 0.000 claims description 7
- 229920000159 gelatin Polymers 0.000 claims description 7
- 239000008273 gelatin Substances 0.000 claims description 7
- 235000019322 gelatine Nutrition 0.000 claims description 7
- 235000011852 gelatine desserts Nutrition 0.000 claims description 7
- 102000008186 Collagen Human genes 0.000 claims description 6
- 108010035532 Collagen Proteins 0.000 claims description 6
- 229920001436 collagen Polymers 0.000 claims description 6
- 150000004676 glycans Chemical class 0.000 claims description 6
- 229920002732 Polyanhydride Polymers 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 229920001577 copolymer Polymers 0.000 claims description 5
- 229920000728 polyester Polymers 0.000 claims description 5
- 229920001282 polysaccharide Polymers 0.000 claims description 5
- 239000005017 polysaccharide Substances 0.000 claims description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- HTWWKYKIBSHDPC-UHFFFAOYSA-N decanoyl decanoate Chemical compound CCCCCCCCCC(=O)OC(=O)CCCCCCCCC HTWWKYKIBSHDPC-UHFFFAOYSA-N 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 229910001021 Ferroalloy Inorganic materials 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- 229910000861 Mg alloy Inorganic materials 0.000 claims description 2
- 229910021529 ammonia Inorganic materials 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229920002627 poly(phosphazenes) Polymers 0.000 claims description 2
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 description 25
- 230000000052 comparative effect Effects 0.000 description 22
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 20
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 20
- 210000002744 extracellular matrix Anatomy 0.000 description 20
- 239000010410 layer Substances 0.000 description 18
- 230000028327 secretion Effects 0.000 description 17
- 238000000034 method Methods 0.000 description 16
- 239000000126 substance Substances 0.000 description 13
- 208000007536 Thrombosis Diseases 0.000 description 12
- 210000003038 endothelium Anatomy 0.000 description 11
- 230000002792 vascular Effects 0.000 description 11
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 230000000877 morphologic effect Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 6
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 235000018417 cysteine Nutrition 0.000 description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
- 210000001105 femoral artery Anatomy 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 5
- 229960002930 sirolimus Drugs 0.000 description 5
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 210000004351 coronary vessel Anatomy 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 206010020718 hyperplasia Diseases 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 238000000889 atomisation Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 239000002121 nanofiber Substances 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 206010048554 Endothelial dysfunction Diseases 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000002473 artificial blood Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 230000009194 climbing Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 230000008694 endothelial dysfunction Effects 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000010147 laser engraving Methods 0.000 description 2
- 238000000707 layer-by-layer assembly Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 238000013146 percutaneous coronary intervention Methods 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- XBBVURRQGJPTHH-UHFFFAOYSA-N 2-hydroxyacetic acid;2-hydroxypropanoic acid Chemical compound OCC(O)=O.CC(O)C(O)=O XBBVURRQGJPTHH-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 201000000057 Coronary Stenosis Diseases 0.000 description 1
- 206010011089 Coronary artery stenosis Diseases 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920004933 Terylene® Polymers 0.000 description 1
- 208000032594 Vascular Remodeling Diseases 0.000 description 1
- 206010072810 Vascular wall hypertrophy Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000003990 capacitor Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- 238000013034 coating degradation Methods 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000011496 digital image analysis Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 201000006828 endometrial hyperplasia Diseases 0.000 description 1
- 230000008753 endothelial function Effects 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 238000001465 metallisation Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001002 morphogenetic effect Effects 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- -1 polytetrafluoroethylene Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000003684 theca cell Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 230000010148 water-pollination Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/145—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/224—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials containing metals, e.g. porphyrins, vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
Abstract
Description
样品 | 内皮化程度 | 细胞外基质分泌状况 |
实施例1 | 细胞形态正常,密集排列,沿支架长轴分布 | 能分泌细胞外基质 |
实施例2 | 细胞形态正常,密集排列,沿支架长轴分布 | 能分泌细胞外基质 |
实施例3 | 细胞形态正常,密集排列,沿支架长轴分布 | 能分泌细胞外基质 |
实施例4 | 细胞形态正常,密集排列,沿支架长轴分布 | 能分泌细胞外基质 |
实施例5 | 细胞形态正常,密集排列,沿支架长轴分布 | 能分泌细胞外基质 |
实施例6 | 细胞形态正常,密集排列,沿支架长轴分布 | 能分泌细胞外基质 |
对比例1 | 基本没有内皮细胞爬覆 | 基本不能分泌细胞外基质 |
对比例2 | 内皮细胞增生严重,形态不均匀 | 能分泌细胞外基质 |
对比例3 | 内皮细胞分布较少,形态不均匀 | 部分能分泌细胞外基质 |
对比例4 | 内皮细胞分布较少,形态不均匀 | 部分能分泌细胞外基质 |
对比例5 | 内皮细胞分布较少,形态不均匀 | 部分能分泌细胞外基质 |
对比例6 | 内皮细胞增生较为严重,形态比较不均匀 | 能分泌细胞外基质 |
对比例7 | 内皮细胞增生较为严重,形态不均匀 | 能分泌细胞外基质 |
对比例8 | 内皮细胞增生较为严重,形态不均匀 | 能分泌细胞外基质 |
对比例9 | 内皮细胞分布较少,形态不均匀 | 部分能分泌细胞外基质 |
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611201213.6A CN106620897B (zh) | 2016-12-22 | 2016-12-22 | 一种抗再狭窄的管腔内支架材料 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611201213.6A CN106620897B (zh) | 2016-12-22 | 2016-12-22 | 一种抗再狭窄的管腔内支架材料 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106620897A CN106620897A (zh) | 2017-05-10 |
CN106620897B true CN106620897B (zh) | 2019-10-18 |
Family
ID=58826549
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611201213.6A Expired - Fee Related CN106620897B (zh) | 2016-12-22 | 2016-12-22 | 一种抗再狭窄的管腔内支架材料 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106620897B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107213512B (zh) * | 2017-06-16 | 2022-07-08 | 南京医科大学第一附属医院 | 一种错时释放双缓释涂层多功能小口径人工血管及其制备方法 |
CN110665072A (zh) * | 2019-11-23 | 2020-01-10 | 吉林省蔚来生物科技有限公司 | 一种靶向药物释放介入类医疗器械及其制备方法 |
CN113648114B (zh) * | 2021-08-25 | 2022-06-24 | 心凯诺医疗科技(上海)有限公司 | 一种涂层支架及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN201006051Y (zh) * | 2006-11-29 | 2008-01-16 | 北京乐普医疗器械有限公司 | 局部多孔洞与少量聚合物共载的药物释放结构 |
CN101322860A (zh) * | 2007-06-12 | 2008-12-17 | 中南大学 | 可降解血管吻合套管及其制备方法 |
CN101161299B (zh) * | 2006-10-09 | 2011-07-06 | 乐普(北京)医疗器械股份有限公司 | 孔洞及聚合物共载的药物释放结构及其制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070196428A1 (en) * | 2006-02-17 | 2007-08-23 | Thierry Glauser | Nitric oxide generating medical devices |
-
2016
- 2016-12-22 CN CN201611201213.6A patent/CN106620897B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101161299B (zh) * | 2006-10-09 | 2011-07-06 | 乐普(北京)医疗器械股份有限公司 | 孔洞及聚合物共载的药物释放结构及其制备方法 |
CN201006051Y (zh) * | 2006-11-29 | 2008-01-16 | 北京乐普医疗器械有限公司 | 局部多孔洞与少量聚合物共载的药物释放结构 |
CN101322860A (zh) * | 2007-06-12 | 2008-12-17 | 中南大学 | 可降解血管吻合套管及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN106620897A (zh) | 2017-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6749626B1 (en) | Actinomycin D for the treatment of vascular disease | |
JP5153340B2 (ja) | 薬剤放出制御組成物および薬剤放出性医療器具 | |
US20080167711A1 (en) | Device And Active Component For Inhibiting Formation Of Thrombus-Inflammatory Cell Matrix | |
US20050064038A1 (en) | Active agent delivery systems including a single layer of a miscible polymer blend, medical devices, and methods | |
JP5816666B2 (ja) | 電気グラフト化されたプライマー被覆を付け、生物分解性放出層を備えた薬物溶離性ステント | |
US20070288088A1 (en) | Drug eluting stent with a biodegradable release layer attached with an electro-grafted primer coating | |
JP2007532187A (ja) | 生物活性物質のためのコーティング組成物 | |
CN114377204A (zh) | 生物可消化性覆盖物及其应用 | |
WO2005018702A2 (en) | Active agent delivery systems including a miscible polymer blend, medical devices, and methods | |
KR20040005936A (ko) | 공동약물을 함유하는 서방 약물 전달 시스템 | |
WO2002085253A1 (en) | Drug delivery platform and methods for the inhibition of neointima formation | |
JP2009523489A (ja) | 被覆医療用具及びその製造方法 | |
US20020119178A1 (en) | Drug eluting device for treating vascular diseases | |
CN101014300A (zh) | 金属药物释放医疗器械及其制造方法 | |
CN101631514A (zh) | 用于经皮冠状动脉介入的多药物洗脱冠状动脉支架 | |
CN106620897B (zh) | 一种抗再狭窄的管腔内支架材料 | |
US20160074562A1 (en) | Drug eluting stent with a biodegradable release layer attached with electro-grafted primer coating | |
CN102091355A (zh) | 一种复合涂层冠脉药物洗脱支架及其制备方法 | |
WO2020087896A1 (zh) | 一种具有抗菌活性的医用可降解聚氨酯及其用途 | |
JP4851086B2 (ja) | 埋め込み型医用機器用のコーティング用組成物及び該機器をコーティングする方法 | |
CN106730049B (zh) | 一种生物相容性内置支架材料 | |
JP2022519171A (ja) | 局所薬剤送達のためのカバードステント | |
CN115486977A (zh) | 一种双开槽双侧单向释放药物支架 | |
KR20160004984A (ko) | 생체적합성 고분자 물질 및 흉터형성 억제약물을 포함하는 의료장치 코팅 제형 | |
WO2001074415A1 (en) | Actinomycin d for the treatment of vascular disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Xie Qiong Inventor after: Li Feng Inventor after: Yi Wenting Inventor after: Shi Jiaming Inventor before: Shi Jiaming |
|
CB03 | Change of inventor or designer information | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190916 Address after: 410005 Department of Cardiovascular Medicine, Hunan People's Hospital, 61 Jiefangxi Road, Changsha City, Hunan Province Applicant after: Hou Geming Address before: Meng Bei Liang Cun town 054200 Xingtai city in Hebei province Neiqiu County No. 274 Applicant before: Shi Jia Ming |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20191205 Address after: 410005 Department of cardiovascular medicine, people's Hospital, No.61, Jiefang West Road, Changsha City, Hunan Province Co-patentee after: Xiangye No. 2 Hospital of Central South University Patentee after: Hou Geming Address before: 410005 Department of Cardiovascular Medicine, Hunan People's Hospital, 61 Jiefangxi Road, Changsha City, Hunan Province Patentee before: Hou Geming |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20191018 Termination date: 20201222 |
|
CF01 | Termination of patent right due to non-payment of annual fee |